文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

接受静脉-静脉体外膜氧合与肾脏替代治疗患者的长期结局:一项回顾性队列研究

Long-term outcomes in patients who received veno-venous extracorporeal membrane oxygenation and renal replacement therapy: a retrospective cohort study.
PubMed 文献 · Ann Intensive Care · 2022-07-23
一句话结论VV-ECMO合并AKI-RRT患者1年死亡率高(32% vs 非AKI 21.4%),出院后肾功能监测不足,1年CKD患病率高达33.3%。

本研究为英国一家ECMO中心的单中心回顾性队列,纳入2010年9月1日至2016年11月30日接受VV-ECMO的成人患者300例,AKI按KDIGO标准定义和分期。主要终点为1年死亡率:AKI-RRT组32% vs 非AKI组21.4%(p=0.014);接受RRT者1年死亡风险高于未接受RRT者(校正HR 1.80,95%CI 1.06–3.06;p=0.029)。中位随访4.35年,ESKD仅3例且均在AKI-RRT组;1年时41.2%存活者有血肌酐结果,其中AKI-RRT组CKD患病率33.3% vs 非AKI组4.3%(p=0.004)。作者认为出院后肾功能监测不足,需提高对这一长期并发症的认识并采取随访干预。

要点

  • VV-ECMO患者AKI发生率达76.7%,其中59.3%接受了RRT。
  • AKI-RRT组1年死亡率为32%,非AKI组为21.4%(p=0.014)。
  • 接受RRT者1年死亡风险高于未接受RRT者(校正HR 1.80,95%CI 1.06–3.06;p=0.029)。
  • 1年时仅41.2%存活者有血肌酐结果,AKI-RRT组CKD患病率33.3% vs 非AKI组4.3%(p=0.004)。
  • ESKD共3例,全部位于AKI-RRT组;中位随访4.35年。

适用人群与场景

  • 英国一家经委托的ECMO中心收治的成人患者(≥18岁),于2010年9月1日至2016年11月30日期间接受VV-ECMO治疗。
  • 最终分析300例:男性57%,中位年龄44.5岁(IQR 34–54);糖尿病12%、高血压17%、CKD 2.3%;严重呼吸衰竭主要病因为肺部感染(72%)。

诊断标准与关键阈值

  • AKI采用肾脏疾病:改善全球结局(KDIGO)分类的血清肌酐和尿量标准进行定义和分期。

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究;样本量300例;人群为接受VV-ECMO的成人患者;暴露为AKI及是否接受RRT。
  • 主要终点1年死亡率:AKI-RRT组32% vs 非AKI组21.4%(p=0.014)。
  • 接受RRT者较未接受RRT者1年死亡风险更高(校正HR 1.80,95%CI 1.06–3.06;p=0.029)。
  • 中位随访时间4.35年;截至2020年3月的长期死亡率为次要终点。
  • ESKD发生3例,均在AKI-RRT组。
  • 1年时41.2%的存活者有血清肌酐结果;其中CKD患病率AKI-RRT组33.3% vs 非AKI组4.3%(p=0.004)。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,VV-ECMO合并AKI-RRT患者长期死亡率高,出院后肾功能监测不足,1年时CKD患病率高(尤其是AKI-RRT患者),需要提高对这一严重长期并发症的认识并采取适当的随访干预。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute kidney injury (AKI) is a frequent complication in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ECMO). However, little is known of long-term kidney function in ECMO survivors. We aimed to assess the long-term mortality and kidney outcomes in adult patients treated with veno-venous ECMO (VV-ECMO).

METHODS: This was a single-centre retrospective study of adult patients (≥ 18 years old) who were treated with VV-ECMO at a commissioned ECMO centre in the UK between 1st September 2010, and 30th November 2016. AKI was defined and staged using the serum creatinine and urine output criteria of the Kidney Diseases: Improving Global Outcomes (KDIGO) classification. The primary outcome was 1-year mortality. Secondary outcomes were long-term mortality (up to March 2020), 1-year incidence of end-stage kidney disease (ESKD) or chronic kidney disease (CKD) among AKI patients who received renal replacement therapy (AKI-RRT), AKI patients who did not receive RRT (AKI-no RRT) and patients without AKI (non-AKI).

RESULTS: A total of 300 patients [57% male; median age 44.5; interquartile range (IQR) 34-54] were included in the final analysis. Past medical histories included diabetes (12%), hypertension (17%), and CKD (2.3%). The main cause of severe respiratory failure was pulmonary infection (72%). AKI occurred in 230 patients (76.7%) and 59.3% received renal replacement therapy (RRT). One-year mortality was 32% in AKI-RRT patients vs. 21.4% in non-AKI patients (p = 0.014). The median follow-up time was 4.35 years. Patients who received RRT had a higher risk of 1-year mortality than those who did not receive RRT (adjusted HR 1.80, 95% CI 1.06, 3.06; p = 0.029). ESKD occurred in 3 patients, all of whom were in the AKI-RRT group. At 1-year, 41.2% of survivors had serum creatinine results available. Among these, CKD was prevalent in 33.3% of AKI-RRT patients vs. 4.3% in non-AKI patients (p = 0.004).

CONCLUSIONS: VV-EMCO patients with AKI-RRT had high long-term mortality. Monitoring of kidney function after hospital discharge was poor. In patients with follow-up creatinine results available, the CKD prevalence was high at 1 year, especially in AKI-RRT patients. More awareness about this serious long-term complication and appropriate follow-up interventions are required.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Lumlertgul N, Wright R, Hutson G, et al. Long-term outcomes in patients who received veno-venous extracorporeal membrane oxygenation and renal replacement therapy: a retrospective cohort study. Ann Intensive Care. 2022. PMID: 35870022. doi:10.1186/s13613-022-01046-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。